Is the FreeStyle Libre 3 continuous glucose monitor covered at no cost for Medicare (Part B) beneficiaries?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medicare Coverage for FreeStyle Libre 3

The FreeStyle Libre 3 is covered by Medicare Part B, but patients typically pay 20% coinsurance after meeting their Part B deductible—it is not provided completely free of charge. 1

Coverage Status and Patient Costs

  • Both FreeStyle Libre systems and Dexcom G6/G7 have achieved broad Medicare eligibility, making them among the most accessible CGM options for Medicare beneficiaries. 1

  • Medicare Part B covers CGM systems as durable medical equipment (DME), with the standard cost-sharing structure requiring beneficiaries to pay 20% of the Medicare-approved amount after meeting their annual Part B deductible. 2

  • The FreeStyle Libre systems have lower direct costs compared to real-time CGM systems, which may result in lower out-of-pocket expenses for the 20% coinsurance portion. 2, 1

Requirements for Ongoing Medicare Coverage

Medicare requires strict documentation to maintain CGM coverage:

  • The device must continuously measure glucose and display data in real-time >95% of the time for the duration specified in the product label. 1

  • Comprehensive reports and validation of glucose values must be documented in electronic health records to support ongoing coverage. 1

  • This documentation requirement is critical—failure to meet these thresholds can result in loss of coverage.

Clinical Eligibility Criteria

Medicare coverage decisions are based on medical necessity:

  • Coverage is well-supported for patients with type 1 diabetes on insulin who require real-time monitoring for optimal glucose control. 1

  • Patients with hypoglycemia unawareness or frequent hypoglycemic episodes have particularly strong justification for CGM coverage. 1

  • Patients with type 2 diabetes on multiple daily insulin injections are also eligible for either real-time or intermittently scanned CGM based on clinical need. 3

FreeStyle Libre 3 Specific Considerations

The FreeStyle Libre 3 is factory-calibrated and does not require fingerstick blood glucose calibrations, which reduces overall monitoring costs and burden. 1

However, be aware of potential accuracy limitations:

  • High doses of acetaminophen, salicylic acid, and ascorbic acid can affect CGM accuracy with glucose oxidase-based sensors like the FreeStyle Libre. 2, 3

  • The system should be used with caution in patients on hemodialysis due to lower accuracy compared to other methods in this population. 2

Common Coverage Pitfalls to Avoid

  • Do not assume "Medicare coverage" means zero cost—the 20% coinsurance still applies unless the patient has supplemental insurance (Medigap) that covers this portion.

  • Ensure patients scan the sensor at minimum once every 8 hours to avoid data gaps that could jeopardize documentation requirements for ongoing coverage. 3

  • Verify that the patient's specific clinical situation meets Medicare's medical necessity criteria before prescribing, as coverage can be denied without proper documentation.

References

Guideline

Insurance Coverage for Continuous Glucose Monitors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Continuous Glucose Monitoring for Diabetes Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.